Maryland Bid to Cap Jardiance Cost Spurs Pushback From Skeptics

A Maryland board’s decision to establish price limits on Eli Lilly and Boehringer Ingelheim‘s blockbuster diabetes drug Jardiance is triggering pushback from the pharmaceutical industry and others who question the benefits for patients.

Maryland’s Prescription Drug Affordability Board is moving to become the second-such entity to set an upper price limit for what state and local government health plans pay for a prescription drug. Setting UPLs, as they’re known, is a controversial authority possessed by only a few state PDABs. Colorado used the power in 2025 over the biologic Enbrel and was swiftly met with litigation from drugmaker Amgen ...